专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140011823A1 NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME 有权
标题翻译：新颖的吡啶衍生物和含有其的药物
公开(公告)号：US20140011823A1
公开(公告)日：2014-01-09
申请号：US14005046
申请日：2012-03-13
申请人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Toshiaki Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Toshiaki Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： C07D413/14 , C07D401/14
CPC分类号： C07D413/14 , A61K31/506 , C07D401/14
摘要： The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPARγ activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.
摘要翻译：本发明提供：下述通式（I）表示的化合物，既具有血管紧张素II受体拮抗作用又具有PPARγ活化作用，可用作高血压，心脏病，动脉硬化等的预防和/或治疗剂， 2型糖尿病等; 和含有该化合物的药物组合物。通式（I）（式中，环A表示吡啶环;环B表示四唑环或恶二唑-5（4H） - 酮环; X表示C-R5或氮原子; R1表示烷基 ; R 2表示烷基或环烷基; R 3，R 4和R 5各自独立地表示氢原子，卤素原子，烷基，烷氧基等。

2. 发明授权

US08531658B2 Measuring chip device using magnets for installation/removal 有权
标题翻译：使用磁铁测量芯片装置进行安装/拆卸
公开(公告)号：US08531658B2
公开(公告)日：2013-09-10
申请号：US13125279
申请日：2009-10-28
申请人： Tsutomu Horiuchi , Toru Miura , Yuzuru Iwasaki , Michiko Seyama , Tsuyoshi Hayashi , Jun-ichi Takahashi , Tsuneyuki Haga
发明人： Tsutomu Horiuchi , Toru Miura , Yuzuru Iwasaki , Michiko Seyama , Tsuyoshi Hayashi , Jun-ichi Takahashi , Tsuneyuki Haga
IPC分类号： G01N21/01
CPC分类号： G01N21/13 , B01L9/527 , B01L2200/025 , B01L2300/0819 , B01L2400/043 , G01N21/553 , G01N2035/00158
摘要： A measuring chip installation/removal device of the present invention secures and removes a measuring chip to and from the top surface of an SPR measurement device that measures a specimen in the measuring chip by surface plasmon resonance. The measuring chip installation/removal device includes: a chip carrier on which the measuring chip is mounted; a chip carrier guide that guides the chip carrier on the top surface; and a first magnet provided in the chip carrier, and a second magnet is provided in the chip carrier guide. Orientation of a magnetic force received by the first magnet from the second magnet is reversed by displacing the chip carrier guide, so that the chip carrier is secured to or removed from the top surface.
摘要翻译：本发明的测量芯片安装/拆卸装置将测量芯片固定并去除测量芯片上的表面等离子体共振测量芯片的SPR测量装置的顶表面。测量芯片安装/拆卸装置包括：安装有测量芯片的芯片载体; 将芯片载体引导到顶表面上的芯片载体引导件; 以及设置在所述芯片载体中的第一磁体，并且在所述芯片载体引导件中设置第二磁体。由第一磁体从第二磁体接收的磁力的方向通过移位芯片载体引导件来反转，使得芯片载体固定到顶表面或从顶表面移除。

3. 发明申请

US20120322819A1 COMPOUND CONTAINING A NOVEL 4-ALKOXYPYRIMIDINE STRUCTURE AND MEDICINE CONTAINING SAME 审中-公开
标题翻译：含有新型4-烷氧基嘧啶结构的化合物和含有其的药物
公开(公告)号：US20120322819A1
公开(公告)日：2012-12-20
申请号：US13580056
申请日：2011-02-25
申请人： Toru Miura , Kazuhiro Onogi , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Kazuhiro Onogi , Junya Tagashira , Gen Watanabe , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： A61K31/506 , C07D413/14 , A61P9/00 , A61P3/04 , A61P9/10 , A61P3/00 , A61P3/10 , C07D413/10 , A61P9/12
CPC分类号： C07D413/10 , C07D413/14
摘要： Disclosed is novel compound and medicinal formulation containing same, possessing both angiotensin II receptor blocking and PPARγ activation effect, of use as a medicine for prevention and/or treatment of hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulatory disturbances, post-ischemic peripheral circulatory damage, renal disease, arteriosclerosis, inflammatory disorder, type 2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinaemia. Further disclosed is the general formula I (where one or both of R1 and R2 represent a C1-6 alkyl group, R3 represents a C1-6 alkyl group which may contain one or more substituent groups selected from group A, or a C3-8 cycloalkyl group which may contain one or more substituent groups selected from group B.) which represents the compound, and salts thereof, solvates thereof, and medicinal compositions containing any of these.
摘要翻译：公开了含有血管紧张素II受体阻断和PPARγ活化作用的新型化合物和药物制剂，用作预防和/或治疗高血压，心脏病，心绞痛，脑血管障碍，脑循环障碍，缺血性外周循环损伤，肾脏疾病，动脉硬化，炎性疾病，2型糖尿病，糖尿病并发症，胰岛素抵抗综合征，X综合征，代谢综合征和高胰岛素血症。进一步公开的是通式I（其中R 1和R 2中的一个或两个表示C 1-6烷基，R 3表示可以含有一个或多个选自A组的取代基的C 1-6烷基或C 3-8 可以含有一个或多个选自B组的取代基的环烷基），其代表该化合物及其盐，其溶剂合物，以及含有这些中的任何一种的药物组合物。

4. 发明授权

US08263025B2 Flow cell 有权
标题翻译：流通池
公开(公告)号：US08263025B2
公开(公告)日：2012-09-11
申请号：US12864854
申请日：2009-01-30
申请人： Toru Miura , Tsutomu Horiuchi , Yuzuru Iwasaki , Michiko Seyama , Serge Camou , Tsuyoshi Hayashi , Jun-ichi Takahashi
发明人： Toru Miura , Tsutomu Horiuchi , Yuzuru Iwasaki , Michiko Seyama , Serge Camou , Tsuyoshi Hayashi , Jun-ichi Takahashi
IPC分类号： G01N15/06 , G01N33/00 , G01N33/48
CPC分类号： G01N21/05 , B01L3/502707 , B01L3/50273 , B01L2300/069 , B01L2300/0816 , B01L2300/0819 , B01L2300/0851 , B01L2300/0887 , B01L2400/0406 , B01L2400/082 , B01L2400/086 , F04B19/006 , G01N21/553 , G01N2021/0346 , G01N2021/056 , Y10T137/85978
摘要： Ends (134a-1) of projections (134a) do not contact a first substrate (11), forming a gap between the ends (134a-1) and the first substrate (11). The internal capacity of a suction pump (17) can be increased by an amount by which the projections (134a) are shortened, compared to a conventional structure in which pillars are formed to connect the ceiling and bottom of the cavity of a capillary pump. The capacity of the suction pump (17) can be increased without enlarging the planar shape. Further, the ends (134a-1) of the projections (134a) do not contact the first substrate (11), forming a gap between them. An impurity can pass through the gap, and clogging of the inside of the suction pump (17) with the impurity can be prevented, realizing a stable operation.
摘要翻译：突起（134a）的端部（134a-1）不接触第一基板（11），在端部（134a-1）和第一基板（11）之间形成间隙。与形成有用于连接毛细管泵的空腔的顶部和底部的柱的常规结构相比，抽吸泵（17）的内部容量可以增加突起（134a）缩短的量。可以增加抽吸泵（17）的容量，而不会扩大平面形状。此外，突起（134a）的端部（134a-1）不与第一基板（11）接触，在它们之间形成间隙。杂质可以通过间隙，并且可以防止吸入泵17的内部与杂质的堵塞，实现稳定的操作。

5. 发明申请

US20120165353A1 NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME 有权
标题翻译：新颖的苯丙氨酸衍生物和药物包括它们
公开(公告)号：US20120165353A1
公开(公告)日：2012-06-28
申请号：US13394266
申请日：2010-09-29
申请人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
发明人： Toru Miura , Seiichi Sato , Hajime Yamada , Junya Tagashira , Ryohei Sekimoto , Rie Ishida , Hitomi Aoki , Tadaaki Ohgiya
IPC分类号： A61K31/506 , C07D413/14 , A61P9/00 , A61P13/12 , A61P3/10 , A61P9/10 , A61P9/12 , C07D401/14 , A61P3/00
CPC分类号： C07D401/14 , A61K31/422 , A61K31/4427 , C07D413/14
摘要： Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents a C1-6 alkyl group; R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group; and R3, R4, R5 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, or a C1-6 alkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.
摘要翻译：公开了一种对血管紧张素II受体具有拮抗作用和PPARγ活化活性的新型化合物，因此可用作高血压，心脏病，动脉硬化，2型糖尿病，糖尿病并发症的预防和/或治疗剂，代谢综合征等; 和含有该化合物的药物组合物。具体公开的是：由通式（I）表示的化合物（其中环A表示吡啶环;环B表示四唑环或恶二唑-5（4H） - 酮环; X表示C-R5或氮原子; R1表示C1-6烷基; R2表示C1-6烷基或C3-8环烷基; R3，R4，R5分别表示氢原子，卤素原子，C1-6烷基，卤代C 1-6烷基或可具有取代基的C 1-6烷氧基），化合物的盐或化合物或其盐的溶剂合物; 和含有该化合物，该盐或溶剂化物的药物组合物。

6. 发明授权

US08205993B2 Projection-type image displaying apparatus 有权
标题翻译：投影型图像显示装置
公开(公告)号：US08205993B2
公开(公告)日：2012-06-26
申请号：US11671277
申请日：2007-02-05
申请人： Toru Miura
发明人： Toru Miura
IPC分类号： G03B21/18
CPC分类号： G03B21/16
摘要： A projection-type image displaying apparatus takes in outside air through an air inlet formed in a housing unit to cool at least one of an optical modulator and an optical element that are accommodated in the housing unit, the optical modulator forming an optical image and the optical element being disposed between the optical modulator and a light source. The projection-type image displaying apparatus includes a cooling fan, a first dustproof filter disposed at the air inlet of the housing unit, a second dustproof filter disposed in a flow path that guides the outside air toward the optical modulator or the optical element after the outside air passes through the first dustproof filter and the cooling fan, and a holder for holding the optical modulator or the optical element, the holder having an outside-air introducing portion, wherein the second dustproof filter is attachable to the outside-air introducing portion.
摘要翻译：投影型图像显示装置通过形成在壳体单元中的空气入口吸入外部空气，以冷却容纳在壳体单元中的光学调制器和光学元件中的至少一个，形成光学图像的光学调制器和光学元件设置在光调制器和光源之间。投影型图像显示装置包括冷却风扇，设置在壳体单元的空气入口处的第一防尘过滤器，设置在流过路径的第二防尘过滤器，该过滤器在外部空气朝向光学调制器或光学元件之后引导外部空气通过第一防尘过滤器和冷却风扇，以及用于保持光学调制器或光学元件的保持器，具有外部空气导入部的保持器，其中第二防尘过滤器可附接到外部空气引入部分。

7. 发明授权

US08012989B2 Substituted pyrimidine compounds and their utility as CETP inhibitors 有权
标题翻译：取代的嘧啶化合物及其作为CETP抑制剂的用途
公开(公告)号：US08012989B2
公开(公告)日：2011-09-06
申请号：US12815905
申请日：2010-06-15
申请人： Tadaaki Ohgiya , Toru Miura , Ayumu Okuda , Toshiharu Arai , Koichi Yamazaki , Taro Aoki , Katsutoshi Miyosawa , Haruki Shibata , Kimiyuki Shibuya
发明人： Tadaaki Ohgiya , Toru Miura , Ayumu Okuda , Toshiharu Arai , Koichi Yamazaki , Taro Aoki , Katsutoshi Miyosawa , Haruki Shibata , Kimiyuki Shibuya
IPC分类号： A61K31/505
CPC分类号： C07D401/12 , C07D403/12 , C07D471/04
摘要： A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl)(lower alkyl) group and the like, R9 represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, R10 and R11 represent hydrogen atom, a lower alkyl group, a lower alkoxy group, a halo(lower alkyl) group and the like, and A represents a heterocyclic ring constituted by 6 to 10 atoms, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).
摘要翻译：由下列通式（I）表示的化合物，其中R 1，R 2，R 3，R 4和R 5表示氢原子，卤原子，低级烷基等，R 6表示烷基，环烷基等，R7和R8表示氢原子，低级烷基，（低级环烷基）（低级烷基）等，R9表示氢原子，卤素原子，低级烷氧基等，R10和R11表示氢原子，低级烷基，低级烷氧基，卤代（低级烷基）等，A表示6〜10个原子构成的杂环，对胆固醇酯转移蛋白（CETP）具有有效的抑制活性。

8. 发明授权

US07961269B2 Optical modulation element unit, projection optical unit, and image projection apparatus 有权
公开(公告)号：US07961269B2
公开(公告)日：2011-06-14
申请号：US12640178
申请日：2009-12-17
申请人： Takehiro Koyama , Toru Miura , Hidetomo Tanaka
发明人： Takehiro Koyama , Toru Miura , Hidetomo Tanaka
IPC分类号： G02F1/1333 , G02F1/1335 , G02F1/153 , G02F1/29 , G03B21/14
CPC分类号： G02F1/133308 , G02F1/133385 , G02F2001/133311 , G02F2201/36 , G03B21/145 , G03B21/16 , H04N9/3144
摘要： An optical modulation element unit is disclosed which employs a film-type optical function member and a reflective optical modulation element and allows dust prevention for the reflective optical modulation element while preventing an increased number of parts other than optically required parts. The optical modulation element unit includes a light-transmissive substrate, a film-type optical function member attached to the light-transmissive substrate, a reflective optical modulation element separately placed from the light-transmissive substrate, a cover member which surrounds a space between the light-transmissive substrate and the reflective optical modulation element, and a holding member which holds the light-transmissive substrate. The holding member has a guide portion which guides an air flow to a space along a surface of the light-transmissive substrate, the surface being a surface on the side opposite to the reflective optical modulation element.

9. 发明授权

US07919509B2 2-oxochromene derivatives 有权
标题翻译： 2-氧代色烯衍生物
公开(公告)号：US07919509B2
公开(公告)日：2011-04-05
申请号：US12394548
申请日：2009-02-27
申请人： Ayumu Okuda , Takayuki Matsuda , Toru Miura , Hidefumi Ozawa , Ayako Tosaka , Koichi Yamazaki , Yuki Yamaguchi , Sayaka Kurobuchi , Yuichiro Watanabe , Kimiyuki Shibuya
发明人： Ayumu Okuda , Takayuki Matsuda , Toru Miura , Hidefumi Ozawa , Ayako Tosaka , Koichi Yamazaki , Yuki Yamaguchi , Sayaka Kurobuchi , Yuichiro Watanabe , Kimiyuki Shibuya
IPC分类号： A61K31/4166 , A61K31/427 , A61K31/45 , A61K31/422 , A61K31/4525 , C07D405/12 , C07D417/12 , C07D413/12 , C07D407/12
CPC分类号： C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D417/12
摘要： To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.[Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.
摘要翻译：提供一种新颖的LXR＆bgr 可用作动脉粥样硬化的预防和/或治疗剂的激动剂; 动脉硬化，如糖尿病引起的; 血脂异常高胆固醇血症脂质相关疾病; 由炎性细胞因子引起的炎性疾病; 皮肤病如过敏性皮肤病; 糖尿病; 或阿尔茨海默病。 [解决方案]由以下通式（1）表示的2-氧代色烯衍生物或其盐或其溶剂合物。

10. 发明申请

US20100307617A1 FLOW CELL 有权
标题翻译：流通池
公开(公告)号：US20100307617A1
公开(公告)日：2010-12-09
申请号：US12864854
申请日：2009-01-30
申请人： Toru Miura , Tsutomu Horiuchi , Yuzuru Iwasaki , Michiko Seyama , Serge Camou , Tsuyoshi Hayashi , Jun-ichi Takahashi
发明人： Toru Miura , Tsutomu Horiuchi , Yuzuru Iwasaki , Michiko Seyama , Serge Camou , Tsuyoshi Hayashi , Jun-ichi Takahashi
IPC分类号： F15D1/00
CPC分类号： G01N21/05 , B01L3/502707 , B01L3/50273 , B01L2300/069 , B01L2300/0816 , B01L2300/0819 , B01L2300/0851 , B01L2300/0887 , B01L2400/0406 , B01L2400/082 , B01L2400/086 , F04B19/006 , G01N21/553 , G01N2021/0346 , G01N2021/056 , Y10T137/85978
摘要： Ends (134a-1) of projections (134a) do not contact a first substrate (11), forming a gap between the ends (134a-1) and the first substrate (11). The internal capacity of a suction pump (17) can be increased by an amount by which the projections (134a) are shortened, compared to a conventional structure in which pillars are formed to connect the ceiling and bottom of the cavity of a capillary pump. The capacity of the suction pump (17) can be increased without enlarging the planar shape. Further, the ends (134a-1) of the projections (134a) do not contact the first substrate (11), forming a gap between them. An impurity can pass through the gap, and clogging of the inside of the suction pump (17) with the impurity can be prevented, realizing a stable operation.
摘要翻译：突起（134a）的端部（134a-1）不接触第一基板（11），在端部（134a-1）和第一基板（11）之间形成间隙。与形成有用于连接毛细管泵的空腔的顶部和底部的柱的常规结构相比，抽吸泵（17）的内部容量可以增加突起（134a）缩短的量。可以增加抽吸泵（17）的容量，而不会扩大平面形状。此外，突起（134a）的端部（134a-1）不与第一基板（11）接触，在它们之间形成间隙。杂质可以通过间隙，并且可以防止吸入泵17的内部与杂质的堵塞，实现稳定的操作。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式